210 related articles for article (PubMed ID: 31477752)
1. Myoferlin silencing inhibits VEGFR2-mediated proliferation of metastatic clear cell renal cell carcinoma.
An HJ; Song DH; Koh HM; Kim YM; Ko GH; Lee JH; Lee JS; Yang JW; Kim MH; Seo DH; Jang SM; Kim DC
Sci Rep; 2019 Sep; 9(1):12656. PubMed ID: 31477752
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
Jung M; Lee C; Park JH; Moon KC
Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma.
Cox A; Zhao C; Tolkach Y; Nettersheim D; Schmidt D; Kristiansen G; Mueller SC; Ritter M; Hauser S; Ellinger J
Anticancer Res; 2020 Jun; 40(6):3119-3128. PubMed ID: 32487606
[TBL] [Abstract][Full Text] [Related]
4. Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition.
Zhang W; Zhou P; Meng A; Zhang R; Zhou Y
J Cell Mol Med; 2018 Mar; 22(3):1743-1754. PubMed ID: 29164766
[TBL] [Abstract][Full Text] [Related]
5. Identification of Myoferlin Expression for Prediction of Subsequent Primary Malignancy in Patients With Clear Cell Renal Cell Carcinoma.
Koh HM; An HJ; Ko GH; Lee JH; Lee JS; Kim DC; Seo DH; Song DH
In Vivo; 2019; 33(4):1103-1108. PubMed ID: 31280198
[TBL] [Abstract][Full Text] [Related]
6. High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma.
Ai Q; Ma X; Huang Q; Liu S; Shi T; Zhang C; Zhu M; Zhang Y; Wang B; Ni D; Li H; Zheng T; Zhang X
PLoS One; 2012; 7(4):e35022. PubMed ID: 22506064
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma.
Ma X; Gu L; Li H; Gao Y; Li X; Shen D; Gong H; Li S; Niu S; Zhang Y; Fan Y; Huang Q; Lyu X; Zhang X
J Transl Med; 2015 Feb; 13():56. PubMed ID: 25740019
[TBL] [Abstract][Full Text] [Related]
8. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
9. An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors.
Gu H; Peng Y; Chen Y
Curr Top Med Chem; 2020; 20(17):1509-1515. PubMed ID: 32552653
[TBL] [Abstract][Full Text] [Related]
10. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
12. High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status.
Kumar B; Brown NV; Swanson BJ; Schmitt AC; Old M; Ozer E; Agrawal A; Schuller DE; Teknos TN; Kumar P
Oncotarget; 2016 Apr; 7(14):18665-77. PubMed ID: 26919244
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway.
Dong D; Mu Z; Wei N; Sun M; Wang W; Xin N; Shao Y; Zhao C
Biomed Pharmacother; 2019 Mar; 111():917-925. PubMed ID: 30841471
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.
Zhang RL; Yang JP; Peng LX; Zheng LS; Xie P; Wang MY; Cao Y; Zhang ZL; Zhou FJ; Qian CN; Bao YX
Cell Cycle; 2016 Nov; 15(22):3094-3104. PubMed ID: 27767378
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma.
Ni D; Ma X; Li HZ; Gao Y; Li XT; Zhang Y; Ai Q; Zhang P; Song EL; Huang QB; Fan Y; Zhang X
Clin Cancer Res; 2014 Apr; 20(7):1779-90. PubMed ID: 24486593
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
Lei Z; Ma X; Li H; Zhang Y; Gao Y; Fan Y; Li X; Chen L; Xie Y; Chen J; Wu S; Tang L; Zhang X
Urol Oncol; 2018 Mar; 36(3):93.e23-93.e37. PubMed ID: 29066014
[TBL] [Abstract][Full Text] [Related]
17. Capn4 contributes to tumor invasion and metastasis in clear cell renal cell carcinoma cells via modulating talin-focal adhesion kinase signaling pathway.
Zhuang Q; Luo W; Zhang M; Fan M; Lu H; Xu R; He X
Acta Biochim Biophys Sin (Shanghai); 2018 May; 50(5):465-472. PubMed ID: 29648579
[TBL] [Abstract][Full Text] [Related]
18. Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling.
He H; Dai J; Zhuo R; Zhao J; Wang H; Sun F; Zhu Y; Xu D
J Cell Physiol; 2018 Dec; 233(12):9503-9515. PubMed ID: 29968912
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
